PMID- 26224690
OWN - NLM
STAT- MEDLINE
DCOM- 20160421
LR  - 20160517
IS  - 2325-9574 (Print)
IS  - 2325-9574 (Linking)
VI  - 15
IP  - 1
DP  - 2016 Jan-Feb
TI  - Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United 
      States.
PG  - 66-76
LID - 10.1177/2325957415594883 [doi]
AB  - OBJECTIVE: To estimate health care costs associated with medical events 
      identified as antiretroviral therapy (ART)-attributable adverse events (AEs). 
      METHODS: During September 2006 to June 2012, adults with >/=1 HIV International 
      Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code 
      (042/V08), >/=1 claim for ART prescription (March 2007-June 2011; index date), and 
      continuous health plan enrollment for >/=6 months pre- and >/=12 months postindex 
      were included (IMS' PharMetrics Plus Health Plan Claims Database). Patients with 
      events of interest/ART claim during preindex period or with pregnancy/hepatitis C 
      virus diagnosis/hepatitis B virus/cancer/tuberculosis during the study period 
      were excluded. Postindex medical events were defined as first diagnosis code of 
      event with ART claim </=60 days prior to start of the event. RESULTS: Differences 
      in median total all-cause health care costs observed for diabetes/insulin 
      resistance management (US$14,547 median all-cause health care costs during time 
      periods identified as diabetes/insulin resistance medical events versus US$11,237 
      without diabetes/insulin resistance events; P=.0021), lipid disorders (US$12,825 
      versus US$10,033; P=.0004), and renal disorders (US$1389 versus US$0; P<.0001). 
      DISCUSSION/CONCLUSION: Health care costs of ART AEs should be key consideration 
      for payers/providers in HIV management.
CI  - (c) The Author(s) 2015.
FAU - Dekoven, Mitch
AU  - Dekoven M
AD  - IMS Health, Fairfax, VA, USA.
FAU - Makin, Charles
AU  - Makin C
AD  - IMS Health, Fairfax, VA, USA.
FAU - Slaff, Samantha
AU  - Slaff S
AD  - Yoh Services LLC, Philadelphia, PA, USA.
FAU - Marcus, Michael
AU  - Marcus M
AD  - IMS Health, Fairfax, VA, USA.
FAU - Maiese, Eric M
AU  - Maiese EM
AD  - Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA emaiese@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150729
PL  - United States
TA  - J Int Assoc Provid AIDS Care
JT  - Journal of the International Association of Providers of AIDS Care
JID - 101603896
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-HIV Agents/*adverse effects/*economics/therapeutic use
MH  - Case-Control Studies
MH  - Databases, Factual
MH  - Drug-Related Side Effects and Adverse Reactions/economics/*epidemiology
MH  - Female
MH  - HIV Infections/*drug therapy/*economics
MH  - Health Care Costs
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - United States/epidemiology
MH  - Young Adult
OTO - NOTNLM
OT  - adverse events
OT  - antiretroviral therapy
OT  - economic burden
OT  - pharmacoeconomics
EDAT- 2015/08/01 06:00
MHDA- 2016/04/22 06:00
CRDT- 2015/07/31 06:00
PHST- 2015/07/31 06:00 [entrez]
PHST- 2015/08/01 06:00 [pubmed]
PHST- 2016/04/22 06:00 [medline]
AID - 2325957415594883 [pii]
AID - 10.1177/2325957415594883 [doi]
PST - ppublish
SO  - J Int Assoc Provid AIDS Care. 2016 Jan-Feb;15(1):66-76. doi: 
      10.1177/2325957415594883. Epub 2015 Jul 29.